These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11117517)

  • 1. PrP fragment 106-126 is toxic to cerebral endothelial cells expressing PrP(C).
    Deli MA; Sakaguchi S; Nakaoke R; Abrahám CS; Takahata H; Kopacek J; Shigematsu K; Katamine S; Niwa M
    Neuroreport; 2000 Nov; 11(17):3931-6. PubMed ID: 11117517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment.
    Brown DR; Herms J; Kretzschmar HA
    Neuroreport; 1994 Oct; 5(16):2057-60. PubMed ID: 7865744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126.
    Stewart LR; White AR; Jobling MF; Needham BE; Maher F; Thyer J; Beyreuther K; Masters CL; Collins SJ; Cappai R
    J Neurosci Res; 2001 Sep; 65(6):565-72. PubMed ID: 11550224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126.
    Jobling MF; Stewart LR; White AR; McLean C; Friedhuber A; Maher F; Beyreuther K; Masters CL; Barrow CJ; Collins SJ; Cappai R
    J Neurochem; 1999 Oct; 73(4):1557-65. PubMed ID: 10501201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment.
    Brown DR; Schmidt B; Kretzschmar HA
    Nature; 1996 Mar; 380(6572):345-7. PubMed ID: 8598929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PrP and beta-amyloid fragments activate different neurotoxic mechanisms in cultured mouse cells.
    Brown DR; Herms JW; Schmidt B; Kretzschmar HA
    Eur J Neurosci; 1997 Jun; 9(6):1162-9. PubMed ID: 9215699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives.
    Poli G; Ponti W; Carcassola G; Ceciliani F; Colombo L; Dall'Ara P; Gervasoni M; Giannino ML; Martino PA; Pollera C; Villa S; Salmona M
    Arzneimittelforschung; 2003; 53(12):875-88. PubMed ID: 14750496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion protein aggregation and neurotoxicity in cortical neurons.
    Melo JB; Agostinho P; Oliveira CR
    Ann N Y Acad Sci; 2007 Jan; 1096():220-9. PubMed ID: 17405933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotoxicity of prion peptides on cultured cerebellar neurons.
    Ciccotosto GD; Cappai R; White AR
    Methods Mol Biol; 2008; 459():83-96. PubMed ID: 18576149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity.
    Salmona M; Forloni G; Diomede L; Algeri M; De Gioia L; Angeretti N; Giaccone G; Tagliavini F; Bugiani O
    Neurobiol Dis; 1997; 4(1):47-57. PubMed ID: 9258911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nonfibrillar form of the fusogenic prion protein fragment [118-135] induces apoptotic cell death in rat cortical neurons.
    Pillot T; Drouet B; Pinçon-Raymond M; Vandekerckhove J; Rosseneu M; Chambaz J
    J Neurochem; 2000 Dec; 75(6):2298-308. PubMed ID: 11080181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of the prion peptide (PrP 106-126) with brain capillary endothelial cells: coordinated cell killing and remodeling of intercellular junctions.
    Cooper I; Cohen-Kashi Malina K; Cagnotto A; Bazzoni G; Salmona M; Teichberg VI
    J Neurochem; 2011 Feb; 116(4):467-75. PubMed ID: 20804519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35.
    Hope J; Shearman MS; Baxter HC; Chong A; Kelly SM; Price NC
    Neurodegeneration; 1996 Mar; 5(1):1-11. PubMed ID: 8731376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion protein peptides: optimal toxicity and peptide blockade of toxicity.
    Brown DR
    Mol Cell Neurosci; 2000 Jan; 15(1):66-78. PubMed ID: 10662506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prion protein fragment interacts with PrP-deficient cells.
    Brown DR; Schmidt B; Kretzschmar HA
    J Neurosci Res; 1998 May; 52(3):260-7. PubMed ID: 9590434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity of prion peptide 106-126 not confirmed.
    Kunz B; Sandmeier E; Christen P
    FEBS Lett; 1999 Sep; 458(1):65-8. PubMed ID: 10518935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amidation and structure relaxation abolish the neurotoxicity of the prion peptide PrP106-126 in vivo and in vitro.
    Bergström AL; Cordes H; Zsurger N; Heegaard PM; Laursen H; Chabry J
    J Biol Chem; 2005 Jun; 280(24):23114-21. PubMed ID: 15824101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prion protein peptide neurotoxicity can be mediated by astrocytes.
    Brown DR
    J Neurochem; 1999 Sep; 73(3):1105-13. PubMed ID: 10461901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidation reduces the fibrillation but not the neurotoxicity of the prion peptide PrP106-126.
    Bergström AL; Chabry J; Bastholm L; Heegaard PM
    Biochim Biophys Acta; 2007 Sep; 1774(9):1118-27. PubMed ID: 17707142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126.
    Jobling MF; Huang X; Stewart LR; Barnham KJ; Curtain C; Volitakis I; Perugini M; White AR; Cherny RA; Masters CL; Barrow CJ; Collins SJ; Bush AI; Cappai R
    Biochemistry; 2001 Jul; 40(27):8073-84. PubMed ID: 11434776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.